title: [Present-day treatment of dyskinesias (author's transl)].
abstract: The physiopathological processes involved in the production of dyskinesias will become clearer as our knowledge of neuromediators and their receptors increases. Among centrally-acting molecules, pimozide and the substituted benzamides block dopaminergic receptors only. Tiapride, which is a substituted benzamide, has an original neurotropic action expressed as relaxant and antidyskinetic activity. It is perfectly well-tolerated and is simple to prescribe, which has made it a product for use in general practice where very encouraging results have been obtained, especially in the two cases reported: an elderly patient with buccofacial dyskinesia often seen in this age group, and a patient with severe dopa-induced dyskinesias.
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D007980:Levodopa
vernacular_title: Traitement actuel des dyskinésies.